Source: Datametrex.
  • Datametrex AI (DM) has received new purchase orders valued at approximately $550K
  •  The POs were received from Lotte Hi-Mart, Lotte Data Communications Co., and Samsung Electronics
  • This follows the $700,000 renewal service contract from LOTTE Data Communications 
  • Datametrex has already received approximately $1.2 million in contracts from existing clients in 2023
  • Datametrex is a technology-focused company with exposure to AI, machine learning, telehealth and the electric vehicle market
  • Datametrex AI Limited (DM) opened trading at C$0.15

Datametrex AI (DM) has received new purchase orders from Lotte Hi-Mart, Lotte Data Communications Co., and Samsung Electronics.

These new contracts, valued at approximately $550K, follow the previously-announced renewal service contract from LOTTE Data Communications. 

So far this year, the company has received approximately $1.2 million in contracts from existing clients for its advanced technology solutions.

Marshall Gunter, CEO of Datametrex, commented on the news.

“We have a sharp focus on our technology solutions, and our constant news flow is an example of that. We are thrilled to start the year off with over $1.2 million in P.O.s and contracts for our technology solutions and look forward to continuing this momentum for the rest of 2023. This is a testament to the hard work and dedication of our team, and we are proud to provide top-notch technology solutions to these companies to improve their operations and stay ahead of the curve.” 

Datametrex is a technology-focused company with exposure to artificial intelligence, machine learning, telehealth and the electric vehicle market.

Datametrex AI Limited (DM) opened trading at C$0.15.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.